Clinical trial of WT1 peptide therapy after WT1 and/or tumor lysates-pulsed dendritic cell vaccination therapy for patients with malignant glioma
Phase 1
Recruiting
- Conditions
- Malignant glioma
- Registration Number
- JPRN-UMIN000008397
- Lead Sponsor
- Group of WT1 peptide therapy in Shinshu Universiry Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) The patient had received the WT1 peptide therapy previously.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The safety and the efficacy of clinical findings and tumor size on MR images are analyzed 12 weeks after the initial WT1 peptide vaccination.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link WT1 peptide therapy to dendritic cell vaccination in malignant glioma immunotherapy?
How does post-dendritic cell vaccination WT1 peptide therapy compare to standard temozolomide in glioblastoma multiforme outcomes?
Which biomarkers correlate with response to tumor lysate-pulsed dendritic cell and WT1 peptide combination therapy in high-grade gliomas?
What adverse events are reported in JPRN-UMIN000008397 Shinshu University Hospital phase I glioma trial?
Are there synergistic combinations of WT1-targeted therapies with PD-1 inhibitors for malignant glioma treatment?